Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approach.
Takeshi HatanakaSatoru KakizakiAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaKeisuke YokohamaHiroki NishikawaTakashi NishimuraNoritomo ShimadaKazuhito KawataHisashi KosakaAtsushi NaganumaYutaka YataHidekatsu KurodaHidekatsu KurodaKazunari TanakaTakaaki TanakaFujimasa TadaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi HiasaMasatoshi KudoTakashi Kumadanull nullPublished in: Cancer medicine (2023)
Using a nonlinear mixed-effects regression approach, which allowed for the inclusion of cases with treatment interruption, we found no significant difference in the trend of liver function deterioration between the Atez/Bev and LEN groups. Caution should be exercised for LEN-treated patients with BCLC advanced stage or those receiving the full dose of LEN.